| Pair Name | Parthenolide, Temozolomide | ||
| Phytochemical Name | Parthenolide (PubChem CID: 7251185 ) | ||
| Anticancer drug Name | Temozolomide (PubChem CID: 5394 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Parthenolide, Temozolomide | |||
| Disease Info | [ICD-11: 2F7Z] | Glioma | Investigative | |
| Gene Regulation | Down-regulation | Activity | NFKB1 | hsa4790 |
| Down-regulation | Expression | MGMT | hsa4255 | |
| Up-regulation | Expression | BAX | hsa581 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| In Vitro Model | T98G | Glioblastoma | Homo sapiens (Human) | CVCL_0556 |
| LN-18 | Glioblastoma | Homo sapiens (Human) | CVCL_0392 | |
| Result | These findings suggest that NF-κB is a potential target for inducing cell death in gliomas. A targeted combination strategy in which the response to TMZ is synergistically enhanced by the addition of parthenolide which may be useful, especially in chemoresistant gliomas with high MGMT expression. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression. Cancer Lett. 2018 Aug 1;428:77-89. doi: 10.1016/j.canlet.2018.04.033. | Click |
